SecBot SecBot
144 ·Filed Jun 15, 2026

RVMD

Revolution Medicines, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago SEC0001246842-26-000002
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

The Form 144 is an advance notice of intent to sell; the actual sale may or may not occur. Given Goldsmith's history of routine RSU-based sales, this filing carries no material signal. Monitor for a subsequent Form 4 to confirm execution. No change to investment thesis.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$156.58
T+0 close · Jun 15, 2026 · via day close
Latest settled
+29.87%
T+60 · $203.35
Vs SPY
+28.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $156.58entry
  2. T+1 · 5mo ago +0.76%α +2.01% · $157.77
  3. T+5 · 5mo ago +8.26%α +10.49% · $169.51
  4. T+20 · 4mo ago +18.13%α +17.93% · $184.97
  5. T+60 · 2mo ago +29.87%α +28.87% · $203.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director and Officer Mark A. Goldsmith filed a Form 144 indicating intent to sell 9,772 shares of Revolution Medicines common stock, valued at approximately $1.5M based on the filing date price. The shares were acquired via restricted stock unit grants in 2023-2025. This is a routine sale consistent with Goldsmith's prior selling pattern (132,871 shares sold in the past three months) and does not signal a change in company outlook.

Key Facts

  • Mark A. Goldsmith (Officer/Director) filed Form 144 to sell 9,772 shares of RVMD common stock.
  • Estimated value of proposed sale: ~$1,503,617.64 (based on ~$153.86/share).
  • Shares to be sold were acquired from RSU grants on 03/01/2023 (3,488 shares), 03/01/2024 (3,018 shares), and 03/01/2025 (3,266 shares).
  • Goldsmith sold 12,871 shares on 03/17/2026 and 120,000 shares on 04/15/2026, totaling 132,871 shares in the prior three months.
  • Company market cap is ~$32.7B; analyst consensus is 96% bullish (26 analysts: 11 Strong Buy, 15 Buy).

Financial Impact

Not specified

Risk Factors

  • Insider selling could be misinterpreted as negative signal by the market, though the pattern is routine.
  • Additional unannounced sales by other insiders could accumulate.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
96% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001246842-26-000002
Document: 0001246842-26-000002-index.html0001246842-26-000002
Document: 0001246842-26-000002.txt0001246842-26-000002

US Market Status

Market Closed · Opens in 8h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026